Published in J Immunol on January 15, 1997
Formation of magnetite by bacteria and its application. J R Soc Interface (2008) 1.13
Superantigen activation of CD4+ and CD8+T cells from HIV-infected subjects: role of costimulatory molecules and antigen-presenting cells (APC) Clin Exp Immunol (1998) 0.95
Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease. Clin Exp Immunol (2003) 0.92
Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. J Clin Invest (1999) 0.85
Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells. Cancer Immunol Immunother (2008) 0.79
Major histocompatibility complex class II- fetal skin dendritic cells are potent accessory cells of polyclonal T-cell responses. Immunology (2000) 0.76
The detection of sLFA-3 in plasma of patients with hemorrhagic fever with renal syndrome. Clin Exp Med (2008) 0.75
Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J Immunol (1989) 2.32
Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J (1995) 1.99
Cerebellar leukoencephalopathy: most likely histiocytosis-related. Neurology (2008) 1.73
Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry (1986) 1.57
Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J (1995) 1.54
Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells. J Immunol (1990) 1.51
Long-term effects of neonatal estrogen treatment on mitogen responsiveness of mouse spleen lymphocytes. J Natl Cancer Inst (1979) 1.49
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci U S A (1994) 1.38
Two subsets of human CD4+ T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies. Eur J Immunol (1988) 1.35
Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics (1997) 1.33
Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med (1995) 1.30
Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. J Immunol (1998) 1.30
A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells. J Immunol (1991) 1.29
Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. J Immunol (1997) 1.29
The crystal structure of staphylococcal enterotoxin type D reveals Zn2+-mediated homodimerization. EMBO J (1996) 1.23
Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A (1991) 1.22
In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors. Proc Natl Acad Sci U S A (1996) 1.21
Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. J Immunol (1992) 1.17
Characterization of individual tumor necrosis factor alpha-and beta-producing cells after polyclonal T cell activation. J Immunol Methods (1989) 1.14
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology (1993) 1.13
Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. J Immunol (1987) 1.13
Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer (1993) 1.11
Superantigens anergize cytokine production but not cytotoxicity in vivo. Immunology (1994) 1.10
Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor. Eur J Immunol (1991) 1.09
T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol (1995) 1.07
Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol (1985) 1.06
Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol (1996) 1.05
Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T cells. Cell Immunol (1991) 1.05
Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation. J Immunol (2000) 1.04
Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother (1993) 1.03
Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology (1990) 1.03
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci U S A (1995) 1.03
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol (1997) 1.02
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology (2002) 1.02
Staphylococcal-enterotoxin-dependent cell-mediated cytotoxicity. Immunol Today (1991) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother (1995) 0.99
Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. Cell Immunol (1996) 0.99
Phenotypical and functional differentiation of CD4+ CD45RA+ human T cells following polyclonal activation. Scand J Immunol (1990) 0.98
Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Am J Pathol (1997) 0.98
Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol (1993) 0.95
Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res (1986) 0.95
Histamine inhibits interleukin 1 production by lipopolysaccharide-stimulated human peripheral blood monocytes. Scand J Immunol (1988) 0.95
Superantigen activation of CD4+ and CD8+T cells from HIV-infected subjects: role of costimulatory molecules and antigen-presenting cells (APC) Clin Exp Immunol (1998) 0.95
Staphylococcal enterotoxin H displays unique MHC class II-binding properties. J Immunol (1999) 0.94
Use of a monoclonal rat anti-mouse Ig light chain (RAMOL-1) antibody reduces background binding in immunohistochemical and fluorescent antibody analysis. J Histochem Cytochem (1989) 0.94
The LFA-3 adhesion pathway is differently utilized by superantigen-activated human CD4+ T-cell subsets. Scand J Immunol (1992) 0.94
Effect of estrogen and corticosterone on the lymphoid system in neonatal mice. Exp Mol Pathol (1978) 0.93
Lymphoid hyperplasia in transgenic mice over-expressing a secreted form of the human interleukin-1beta gene product. Immunology (1999) 0.93
Staphylococcal enterotoxin D is a promiscuous superantigen offering multiple modes of interactions with the MHC class II receptors. J Immunol (1998) 0.93
Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer (2001) 0.93
Role of the adhesion molecule ICAM-1 (CD54) in staphylococcal enterotoxin-mediated cytotoxicity. Eur J Immunol (1991) 0.92
Superantigen-induced anergy in cytotoxic CD8+ T cells. J Immunol (1995) 0.92
Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity. Curr Top Microbiol Immunol (1991) 0.91
Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. Adv Exp Med Biol (2000) 0.91
Genetically engineered superantigens as tolerable antitumor agents. Proc Natl Acad Sci U S A (1997) 0.91
Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur J Immunol (1994) 0.91
Staphylococcal enterotoxins direct and trigger CTL killing of autologous HLA-DR+ mononuclear leukocytes and freshly prepared leukemia cells. Cell Immunol (1990) 0.91
The Co-crystal structure of staphylococcal enterotoxin type A with Zn2+ at 2.7 A resolution. Implications for major histocompatibility complex class II binding. J Biol Chem (1996) 0.90
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer (2007) 0.90
Reduced natural killer activity in female mice after neonatal exposure to diethylstilbestrol. J Immunol (1980) 0.89